MELANOTAN II PEPTIDE 10MG VIAL

Melanotan II (MT2) Peptide

This information is for educational purposes only. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

References

[1] D. J. Callaghan Iii, “A glimpse into the underground market of melanotan,” Dermatol. Online J., 2018.

[2] J. C. Wu, H. E. Tsai, Y. H. Hsiao, J. S. Wu, C. S. Wu, and M. H. Tai, “Topical MTII therapy suppresses melanoma through PTEN upregulation and cyclooxygenase II inhibition,” Int. J. Mol. Sci., 2020.

[3] H. Chen, Q. Y. Weng, and D. E. Fisher, “UV signaling pathways within the skin,” Journal of Investigative Dermatology. 2014.

[4] N. G. Jablonski and G. Chaplin, “Human skin pigmentation as an adaptation to UV radiation,” Proc. Natl. Acad. Sci. U. S. A., 2010.

[5] M. Yaar and B. A. Gilchrest, “Photoageing: Mechanism, prevention and therapy,” British Journal of Dermatology. 2007.

[6] J. M. Jeter et al., “Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials,” Cancer. 2019.

[7] E. Minakova et al., “Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism,” PLoS One, 2019.

[8] F. Giuliano, P. Clément, S. Droupy, L. Alexandre, and J. Bernabé, “Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat,” Neuroscience, 2006.

[9] M. E. Hadley, “Discovery that a melanocortin regulates sexual functions in male and female humans,” Peptides. 2005.

[10] Trevor J. Hallam, Carl Spana, Dennis C. Earle, Annette M. Shadiack, and Shubh D. Sharma, “Melanocortins in the Treatment of Male and Female Sexual Dysfunction,” Curr. Top. Med. Chem., 2007.

[11] S. Ückert, A. Bannowsky, K. Albrecht, and M. A. Kuczyk, “Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: Results from basic research and clinical studies,” Expert Opinion on Investigational Drugs. 2014.

[12] G. M. Sutton, B. Duos, L. M. Patterson, and H. R. Berthoud, “Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through ERK signaling in rat solitary nucleus,” Endocrinology, 2005.

[13] E. Keen-Rhinehart and T. J. Bartness, “MTII attenuates ghrelin- and food deprivation-induced increases in food hoarding and food intake,” Horm. Behav., 2007.

[14] S. Boghossian, M. Park, and D. A. York, “Melanocortin activity in the amygdala controls appetite for dietary fat,” Am. J. Physiol. - Regul. Integr. Comp. Physiol., 2010.

[15] C. A. Campos and R. C. Ritter, “Nmda-type glutamate receptors participate in reduction of food intake following hindbrain melanocortin receptor activation,” Am. J. Physiol. - Regul. Integr. Comp. Physiol., 2015.

[16] H. R. Berthoud, G. M. Sutton, R. L. Townsend, L. M. Patterson, and H. Zheng, “Brainstem mechanisms integrating gut-derived satiety signals and descending forebrain information in the control of meal size,” Physiol. Behav., 2006.

[17] S. M. Luckman, “Brainstem-hypothalamic neuropeptides and the regulation of feeding,” in Appetite and Body Weight, 2007.

[18] I. Côté et al., “Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction,” Can. J. Physiol. Pharmacol., 2017.

[19] A. A. Butler and R. D. Cone, “The melanocortin receptors: Lessons from knockout models,” Neuropeptides, 2002.

[20] A. A. Butler, “The melanocortin system and energy balance,” Peptides. 2006.

[21] B. Monge-Roffarello et al., “The medial preoptic nucleus as a site of the thermogenic and metabolic actions of melanotan II in male rats,” Am. J. Physiol. - Regul. Integr. Comp. Physiol., 2014.

[22] D. D. Pierroz, M. Ziotopoulou, L. Ungsunan, S. Moschos, J. S. Flier, and C. S. Mantzoros, “Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity,” Diabetes, 2002.

[23] J. W. Anderson, E. C. Konz, R. C. Frederich, and C. L. Wood, “Long-term weight-loss maintenance: A meta-analysis of US studies,” Am. J. Clin. Nutr., 2001.

[24] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2018,” CA. Cancer J. Clin., 2018.

[25] Q. Liu, M. Das, Y. Liu, and L. Huang, “Targeted drug delivery to melanoma,” Advanced Drug Delivery Reviews. 2018.

[26] C. Lee, J. A. Ramirez, J. Guitart, and L. K. Diaz, “Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression,” J. Cutan. Pathol., 2008.

[27] R. Basson, M. E. Wierman, J. van Lankveld, and L. Brotto, “Summary of the recommendations on sexual dysfunctions in women,” J. Sex. Med., 2010.

[28] F. Montorsi et al., “Summary of the recommendations on sexual dysfunctions in men,” J. Sex. Med., 2010.

[29] D. Hatzichristou et al., “Recommendations for the clinical evaluation of men and women with sexual dysfunction,” J. Sex. Med., 2010.

[30] D. Hatzichristou et al., “Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires,” J. Sex. Med., 2016.

[31] H. Wessells et al., “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Double-blind, placebo controlled crossover study,” J. Urol., 1998.

[32] H. Wessells, N. Levine, M. E. Hadley, R. Dorr, and V. Hruby, “Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II,” Int. J. Impot. Res., 2000.

[33] L. E. Diamond, D. C. Earle, J. R. Heiman, R. C. Rosen, M. A. Perelman, and R. Harning, “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by Bremelanotide (PT-141), a melanocortin receptor agonist,” J. Sex. Med., 2006.

[34] M. R. Safarinejad, “Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: A double-blind placebo-controlled, fixed dose, randomized study,” J. Sex. Med., 2008.

 

*The information herein is for educational and informational purposes only. THIS PRODUCT IS FOR RESEARCH USE ONLY. For use in animal studies, all research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Storage: Lyophilized peptide should be stored at -20°C (freezer), and the reconstituted peptide solution at 4°C (refrigerated). Do not freeze once reconstituted.